BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation
Volume 3, Issue 4 , Pages 187-199 , October 2010

Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study

This work was presented in poster format at the Annual Meeting of Biological Psychiatry 2007.

  • Philip G. Janicak

      Affiliations

    • Rush University Medical Center, Chicago, Illinois
    • Corresponding Author InformationCorrespondence: Philip G. Janicak, MD, Department of Psychiatry, Rush University Medical Center, 2150 W Harrison St, Chicago, IL 60612.
    • ,
  • Ziad Nahas

      Affiliations

    • Medical University of South Carolina, Charleston, South Carolina
    • ,
  • Sarah H. Lisanby

      Affiliations

    • Columbia University, New York State Psychiatric Institute, New York, New York
    • ,
  • H. Brent Solvason

      Affiliations

    • Stanford University Medical Center, Palo Alto, California
    • ,
  • Shirlene M. Sampson

      Affiliations

    • Mayo Clinic, Rochester, Minnesota
    • ,
  • William M. McDonald

      Affiliations

    • Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Lauren B. Marangell

      Affiliations

    • Baylor College of Medicine, Houston, Texas
    • ,
  • Peter Rosenquist

      Affiliations

    • Wake Forest University Health Sciences, Winston-Salem, North Carolina
    • ,
  • W. Vaughn McCall

      Affiliations

    • Wake Forest University Health Sciences, Winston-Salem, North Carolina
    • ,
  • James Kimball

      Affiliations

    • Wake Forest University Health Sciences, Winston-Salem, North Carolina
    • ,
  • John P. O’Reardon

      Affiliations

    • University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
    • ,
  • Colleen Loo

      Affiliations

    • University of New South Wales, Black Dog Institute, Sydney, Australia
    • ,
  • Mustafa H. Husain

      Affiliations

    • University of Texas Southwestern Medical School, Dallas, Texas
    • ,
  • Andrew Krystal

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • ,
  • William Gilmer

      Affiliations

    • Northwestern University, Feinberg School of Medicine, Chicago, Illinois
    • ,
  • Sheila M. Dowd

      Affiliations

    • Rush University Medical Center, Chicago, Illinois
    • ,
  • Mark A. Demitrack

      Affiliations

    • Neuronetics, Inc., Malvern, Pennsylvania
    • ,
  • Alan F. Schatzberg

      Affiliations

    • Stanford University Medical Center, Palo Alto, California

Received 20 April 2010 ,Revised 8 July 2010 ,Accepted 13 July 2010.

References 

  1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry. 2006;163:1905–1917
  2. O’Reardon JP, Solvason B, Janicak PG, et al. Efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in the acute treatment of major depression: results of a multicenter randomized ontrolled trial. Biol Psychiatry. 2007;62:1208–1216
  3. Janicak PG, O’Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry. 2008;69:222–232
  4. Avery DH, Isenberg KE, Sampson SM, et al. TMS in the acute treatment of major depression: clinical response in an open-label extension trial. J Clin Psychiatry. 2008;69:441–451
  5. Lisanby SH, Husain MM, Rosenquist PB, et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology. 2009;34:522–534
  6. Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull. 2009;42:5–38
  7. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder. Arch Gen Psychiatry. 2010;67:507–516
  8. Dannon PN, Dolberg OT, Schreiber S, Grunhaus L. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals—preliminary report. Biol Psychiatry. 2002;51:687–690
  9. O’Reardon JP, Blumner KH, Peshek AD, Pradilla RR, Pimiento PC. Long-term maintenance therapy for major depressive disorder with rTMS. J Clin Psychiatry. 2005;66:1524–1528
  10. Fitzgerald PB, Benitez J, de Castella AR, Brown TL, Daskalakis ZJ, Kulkarni J. Naturalistic study of the use of transcranial magnetic stimulation in the treatment of depressive relapse. Aust N Z J Psychiatry. 2006;40:764–768
  11. Demirtas-Tatlidede A, Mechanic-Hamilton D, Press DZ, et al. An open-label, prospective study of repetitive transcranial magnetic stimulation (rTMS) in the long-term treatment of refractory depression: reproducibility and duration of the antidepressant effect in medication-free patients. J Clin Psychiatry. 2008;69:930–934
  12. Cohen RB, Boggio PS, Fregni F. Risk factors for relapse after remision with repetitive transcranial magnetic stimulation for the treatment of depression. Depress Anxiety. 2009;26:682–688
  13. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J. Training and quality assurance with the structured clinical interview for DSM-IV (SCID-I/P). Psychiatry Res. 1998;79:163–167
  14. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):10–17
  15. Williams N, Simpson AN, Simpson K, Nahas Z. Relapse rates with long-term antidepressant drug therapy: a meta-analysis. Hum Psychopharmacol Clin Exp. 2009;24:401–408
  16. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285:1299–1307
  17. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry. 2004;55:301–302
  18. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research In Electroconvulsive Therapy (CORE). Arch Gen Psychiatry. 2006;63:1337–1344
  19. Tew JD, Mulsant BH, Haskett RF, Joan P, Begley AE, Sackeim HA. Relapse during continuation pharmacotherapy after acute response to ECT: a comparison of usual care versus protocolized treatment. Ann Clin Psychiatry. 2007;19:1–4
  20. Rusjan PM, Barr MS, Farzan F, et al. Optimal transcranial magnetic stimulation coil placement for targeting the dorsolateral prefrontal cortex using novel magnetic resonance image-guided neuronavigation. [published online ahead of print February 16, 2010] Hum Brain Mapp. 2010;

 Supported by a grant from Neuronetics Inc. (Grant 44-01103-000).

 Clinical trial posted on www.clinicaltrials.gov. Listing No. NCT 00104611.

 L.B.M. is currently employed at Eli Lilly and Company, Indianapolis, IN.

PII: S1935-861X(10)00110-5

doi: 10.1016/j.brs.2010.07.003

BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation
Volume 3, Issue 4 , Pages 187-199 , October 2010

Article Tools

* Image Usage & Resolution